Dr. David T. Yeung - CML - Chronic myeloid leukemia
"David Yeung is a postdoctoral research fellow with the Precision Medicine Theme at the SHAMRI. He also has positions with the Royal Adelaide Hospital and SA Pathology as a practicing haematologist and haemato-pathologist, and has affiliations with both the University of Adelaide and the University of South Australia. He had training in clinical and laboratory haematology in Sydney before completing his PhD in Adelaide. His focus is on improving outcomes for patients with chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL). Along with Prof Tim Hughes, David leads several national CML clinical trials, with the aim of optimising the use to tyrosine kinase inhibitors leading to improved efficacy and reduced toxicity. Innovative correlative study research projects attached to this clinical trials allow further understand of the biology underlying resistant cases"
Extract from SAHMRI
ARTICLES
Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study
November 13, 2019, Blood Journal
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
July 24, 2014, Blood Journal
Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study
November 13, 2019, Blood Journal
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
July 24, 2014, Blood Journal